vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $66.0M, roughly 1.1× SOLENO THERAPEUTICS INC). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs 39.4%, a 0.5% gap on every dollar of revenue.
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
ARI vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $66.0M |
| Net Profit | $29.2M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | 39.7% | 33.5% |
| Net Margin | 39.9% | 39.4% |
| Revenue YoY | 4.0% | — |
| Net Profit YoY | -28.2% | 134.0% |
| EPS (diluted) | $0.19 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | — | ||
| Q3 25 | $61.6M | $66.0M | ||
| Q2 25 | $70.9M | $32.7M | ||
| Q1 25 | $65.8M | — | ||
| Q4 24 | $70.5M | — | ||
| Q3 24 | $71.6M | — | ||
| Q2 24 | $81.1M | — | ||
| Q1 24 | $80.5M | — |
| Q4 25 | $29.2M | — | ||
| Q3 25 | $50.8M | $26.0M | ||
| Q2 25 | $20.7M | $-4.7M | ||
| Q1 25 | $26.0M | — | ||
| Q4 24 | $40.7M | — | ||
| Q3 24 | $-91.5M | — | ||
| Q2 24 | $35.8M | — | ||
| Q1 24 | $-104.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 39.7% | — | ||
| Q3 25 | 82.8% | 33.5% | ||
| Q2 25 | 29.4% | -20.0% | ||
| Q1 25 | 39.7% | — | ||
| Q4 24 | 57.9% | — | ||
| Q3 24 | -127.8% | — | ||
| Q2 24 | 44.2% | — | ||
| Q1 24 | -129.6% | — |
| Q4 25 | 39.9% | — | ||
| Q3 25 | 82.4% | 39.4% | ||
| Q2 25 | 29.3% | -14.4% | ||
| Q1 25 | 39.5% | — | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -127.9% | — | ||
| Q2 24 | 44.1% | — | ||
| Q1 24 | -129.8% | — |
| Q4 25 | $0.19 | — | ||
| Q3 25 | $0.34 | $0.47 | ||
| Q2 25 | $0.12 | $-0.09 | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $-0.69 | — | ||
| Q2 24 | $0.23 | — | ||
| Q1 24 | $-0.76 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $494.8M |
| Total Assets | $9.9B | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | — | ||
| Q3 25 | $245.9M | $498.9M | ||
| Q2 25 | $177.6M | $286.8M | ||
| Q1 25 | $166.4M | — | ||
| Q4 24 | $317.4M | — | ||
| Q3 24 | $194.3M | — | ||
| Q2 24 | $174.7M | — | ||
| Q1 24 | $161.2M | — |
| Q4 25 | $1.9B | — | ||
| Q3 25 | $1.9B | $494.8M | ||
| Q2 25 | $1.8B | $240.1M | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $9.9B | — | ||
| Q3 25 | $9.5B | $599.9M | ||
| Q2 25 | $9.8B | $332.3M | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $8.4B | — | ||
| Q3 24 | $9.1B | — | ||
| Q2 24 | $9.3B | — | ||
| Q1 24 | $9.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 4.88× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | — | ||
| Q3 25 | $31.7M | $43.5M | ||
| Q2 25 | $63.2M | $-12.6M | ||
| Q1 25 | $39.3M | — | ||
| Q4 24 | $200.3M | — | ||
| Q3 24 | $47.2M | — | ||
| Q2 24 | $50.2M | — | ||
| Q1 24 | $52.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | 1.67× | ||
| Q2 25 | 3.05× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | 4.93× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
